The workings of the amyloid diseases

References

• Merlini G., Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349: 583–96
   PubMed Web of Science ®Google Scholar
• Relini A., Rolandi R., Bolognesi M., Aboudan M., Merlini G., Bellotti V., et al. Ultrastructural organization of ex vivo amyloid fibrils formed by the apolipoprotein A–I Leu174Ser variant: an atomic force microscopy study. Biochim Biophys Acta 2004; 1690: 33–41
   PubMed Web of Science ®Google Scholar
• Serpell L. C., Sunde M., Benson M. D., Tennent G. A., Pepys M. B., Fraser P. E. The protofilament substructure of amyloid fibrils. J Mol Biol 2000; 300: 1033–9
   PubMed Web of Science ®Google Scholar
• Merlini G., Bellotti V. Lysozyme: a paradigmatic molecule for the investigation of protein structure, function and misfolding. Clin Chim Acta 2005; 357: 168–72
   PubMed Web of Science ®Google Scholar
• Perfetti V., Casarini S., Palladini G., Vignarelli M. C., Klersy C., Diegoli M., et al. Analysis of V lambda–J lambda expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambda III) as a new amyloid‐associated germline gene segment. Blood 2002; 100: 948–53
   PubMed Web of Science ®Google Scholar
• Wetzel R. Domain stability in immunoglobulin light chain deposition disorders. Adv Protein Chem 1997; 50: 183–242
   PubMedGoogle Scholar
• Esposito G., Garcia J., Mangione P., Giorgetti S., Corazza A., Viglino P., et al. Structural and folding dynamics properties of T70N variant of human lysozyme. J Biol Chem 2003; 28: 25190–8
   Google Scholar
• Johnson R. J., Christodoulou J., Dumoulin M., Caddy G. L., Alcocer M. J., Murtagh G. J., et al. Rationalising lysozyme amyloidosis: insights from the structure and solution dynamics of T70N lysozyme. J Mol Biol 2005; 352: 823–36
   PubMed Web of Science ®Google Scholar
• Sebastiao M. P., Lamzin V., Saraiva M. J., Damas A. M. Transthyretin stability as a key factor in amyloidogenesis: X‐ray analysis at atomic resolution. J Mol Biol 2001; 306: 733–44
   PubMed Web of Science ®Google Scholar
• Chiti F., Calamai M., Taddei N., Stefani M., Ramponi G., Dobson C. M. Studies of the aggregation of mutant proteins in vitro provide insights into the genetics of amyloid diseases. Proc Natl Acad Sci U S A 2002; 99(Suppl 4)16419–26
   PubMed Web of Science ®Google Scholar
• Fernandez‐Escamilla A. M., Rousseau F., Schymkowitz J., Serrano L. Prediction of sequence‐dependent and mutational effects on the aggregation of peptides and proteins. Nat Biotechnol 2004; 22: 1302–6
   PubMed Web of Science ®Google Scholar
• Chiti F., Dobson C. M. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 2006; 75: 333–66
   PubMed Web of Science ®Google Scholar
• Carrell R. W., Lomas D. A. Conformational disease. Lancet 1997; 350: 134–8
   PubMed Web of Science ®Google Scholar
• Perutz M. F. Amyloid fibrils. Mutations make enzymes polymerize. Nature 1997; 385: 773–5
   PubMed Web of Science ®Google Scholar
• Tennent G. A., Lovat L. B., Pepys M. B. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci U S A 1995; 92: 4299–303
   PubMed Web of Science ®Google Scholar
• Kisilevsky R. Review: Amyloidogenesis—unquestioned answers and unanswered questions. J Struct Biol 2000; 130: 99–108
   PubMed Web of Science ®Google Scholar
• Castillo G. M., Lukito W., Wight T. N., Snow A. D. The sulfate moieties of glycosaminoglycans are critical for the enhancement of beta‐amyloid protein fibril formation. J Neurochem 1999; 72: 1681–7
   PubMed Web of Science ®Google Scholar
• Diaz‐Nido J., Wandosell F., Avila J. Glycosaminoglycans and beta‐amyloid, prion and tau peptides in neurodegenerative diseases. Peptides 2002; 23: 1323–32
   PubMed Web of Science ®Google Scholar
• Yamamoto S., Yamaguchi I., Hasegawa K., Tsutsumi S., Goto Y., Gejyo F., et al. Glycosaminoglycans enhance the trifluoroethanol‐induced extension of beta(2)‐microglobulin‐related amyloid fibrils at a neutral pH. J Am Soc Nephrol 2004; 15: 126–33
   PubMed Web of Science ®Google Scholar
• Suk J. Y., Zhang F., Balch W. E., Linhardt R. J., Kelly J. W. Heparin accelerates gelsolin amyloidogenesis. Biochemistry 2006; 45: 2234–42
   PubMed Web of Science ®Google Scholar
• Li J. P., Galvis M. L., Gong F., Zhang X., Zcharia E., Metzger S., et al. In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis. Proc Natl Acad Sci U S A 2005; 102: 6473–7
   PubMed Web of Science ®Google Scholar
• Relini A., Canale C., De Stefano S., Rolandi R., Giorgetti S., Stoppini M., et al. Collagen plays an active role in the aggregation of beta 2‐microglobulin under physio‐pathological conditions of dialysis‐related amyloidosis. J Biol Chem 2006; 24: 16521–9
   Google Scholar
• Lambert M. P., Barlow A. K., Chromy B. A., Edwards C., Freed R., Liosatos M., et al. Diffusible, nonfibrillar ligands derived from Abeta1‐42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 1998; 95: 6448–53
   PubMed Web of Science ®Google Scholar
• Hartley D. M., Walsh D. M., Ye C. P., Diehl T., Vasquez S., Vassilev P. M., et al. Protofibrillar intermediates of amyloid beta‐protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 1999; 19: 8876–84
   PubMed Web of Science ®Google Scholar
• Andersson K., Olofsson A., Nielsen E. H., Svehag S. E., Lundgren E. Only amyloidogenic intermediates of transthyretin induce apoptosis. Biochem Biophys Res Commun 2002; 294: 309–14
   PubMed Web of Science ®Google Scholar
• Pepys M. B. Amyloidosis. Annu Rev Med 2006; 57: 223–41
   PubMed Web of Science ®Google Scholar
• Cecchi C., Pensalfini A., Baglioni S., Fiorillo C., Caporale R., Formigli L., et al. Differing molecular mechanisms appear to underlie early toxicity of prefibrillar HypF‐N aggregates to different cell types. FEBS J 2006; 273: 2206–22
   PubMed Web of Science ®Google Scholar
• Palladini G., Campana C., Klersy C., Balduini A., Vadacca G., Perfetti V., et al. Serum N‐terminal pro‐brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003; 107: 2440–5
   PubMed Web of Science ®Google Scholar
• Palladini G., Lavatelli F., Russo P., Perlini S., Perfetti V., Bosoni T., et al. Circulating amyloidogenic free light chains and serum N‐terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL amyloidosis. Blood 2006; 10: 3854–8
   Google Scholar
• Carulla N., Caddy G. L., Hall D. R., Zurdo J., Gairi M., Feliz M., et al. Molecular recycling within amyloid fibrils. Nature 2005; 436: 554–8
   PubMed Web of Science ®Google Scholar
• Niewold T. A., Gruys E., Kisilevsky R., Shirahama T. S. Fibril amyloid enhancing factor (FAEF)‐accelerated amyloidosis in the hamster is not dependent on serine esterase activity and mononuclear phagocytosis. Scand J Immunol 1991; 34: 101–7
   PubMed Web of Science ®Google Scholar
• Jarrett J. T., Lansbury P. T., Jr. Seeding ‘one‐dimensional crystallization’ of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie?. Cell 1993; 73: 1055–8
   PubMed Web of Science ®Google Scholar
• Kelly J. W. Mechanisms of amyloidogenesis. Nat Struct Biol 2000; 7: 824–6
   PubMedGoogle Scholar
• Ganowiak K., Hultman P., Engstrom U., Gustavsson A., Westermark P. Fibrils from synthetic amyloid‐related peptides enhance development of experimental AA‐amyloidosis in mice. Biochem Biophys Res Commun 1994; 199: 306–12
   PubMed Web of Science ®Google Scholar
• Johan K., Westermark G., Engstrom U., Gustavsson A., Hultman P., Westermark P. Acceleration of amyloid protein A amyloidosis by amyloid‐like synthetic fibrils. Proc Natl Acad Sci U S A 1998; 95: 2558–63
   PubMed Web of Science ®Google Scholar
• Lundmark K., Westermark G. T., Nystrom S., Murphy C. L., Solomon A., Westermark P. Transmissibility of systemic amyloidosis by a prion‐like mechanism. Proc Natl Acad Sci U S A 2002; 99: 6979–84
   PubMed Web of Science ®Google Scholar
• Olofsson B. O., Backman C., Karp K., Suhr O. B. Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type. Transplantation 2002; 73: 745–51
   PubMed Web of Science ®Google Scholar
• Yazaki M., Tokuda T., Nakamura A., Higashikata T., Koyama J., Higuchi K., et al. Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild‐type transthyretin. Biochem Biophys Res Commun 2000; 274: 702–6
   PubMed Web of Science ®Google Scholar